Please login to the form below

Not currently logged in
Email:
Password:

Algeta

This page shows the latest Algeta news and features for those working in and with pharma, biotech and healthcare.

Bayer CEO Dekkers points to 'outstanding' pharma growth

Bayer CEO Dekkers points to 'outstanding' pharma growth

9bn it paid for the drug's developer Algeta last December.

Latest news

  • Bayer buys Chinese consumer care company Bayer buys Chinese consumer care company

    Bayer buys Chinese consumer care company. Acquires Dihon Pharmaceutical as Algeta takeover closes. ... year. By the extended deadline of February 26 the company had agreements to acquire a little over 97 per cent of Algeta's stock.

  • Bayer agrees $2.9bn deal for Algeta to get Xofigo control Bayer agrees $2.9bn deal for Algeta to get Xofigo control

    Bayer agrees $2.9bn deal for Algeta to get Xofigo control. Raises initial offer to buy Norweigan pharma company. ... Bayer has reached an agreement to buy Norwegian pharma company Algeta after raising its offer to around $2.9bn.

  • Bayer offers $2.4bn to buy Xofigo partner Algeta Bayer offers $2.4bn to buy Xofigo partner Algeta

    Bayer offers $2.4bn to buy Xofigo partner Algeta. Norwegian firm says negotiations still at 'an early stage'. ... One unanswered question is whether Algeta has some other hidden gems in its pipeline.

  • EU approval for Bayer’s prostate cancer drug EU approval for Bayer’s prostate cancer drug

    Bayer acquired Xofigo from Norwegian company Algeta in 2009. The deal granted full commercialisation rights in Europe to Bayer while in the US Bayer co-promotes the drug with Algeta.

  • Roche's Kadcyla and Bayer's Xofigo near EU approval Roche's Kadcyla and Bayer's Xofigo near EU approval

    The CHMP also gave its blessing to Bayer and Algeta's Xofigo (radium Ra 223 dichloride) for castration-resistant prostate cancer (CRPC ). In the case of Kadcyla (trastuzumab emtansine), the CHMP ... Algeta said last month Xofigo had got off to a good

More from news
Approximately 4 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Bayer paid 50m ($68m) upfront payment with further milestones in return for global rights which should complement Xofigo (from the acquisition of Algeta).

  • Pharma deals during November 2013 Pharma deals during November 2013

    Algeta, has been noted as being rather ungenerous, with room for upping the offer. ... Assuming this acquisition goes through, this buys out the previous deal with Algeta under which there was US co-promotion for 50 per cent of in-country profits, plus

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Hyperlipidemia. 2, 600. Algeta / Bayer. Acquisition. Buys out deal for Xofigo radiotherapeutic for.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Targovax appoints chief financial officer Targovax appoints chief financial officer

    He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey &Company's pharma and healthcare practice.

  • Targovax appoints Oystein Soug as CEO Targovax appoints Oystein Soug as CEO

    He has previously served as chief financial officer for Algeta, a Norwegian oncology biotech that was bought by Bayer in 2014, and spent six years at Orkla, a Norwegian consumer goods

  • Algeta execs join Targovax Algeta execs join Targovax

    Algeta execs join Targovax. Anna-Kirsti Aksnes and Tina Madsen join the firm. ... Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics